Enterprise Value

40.38M

Cash

201.9M

Avg Qtr Burn

-27.18M

Short % of Float

4.62%

Insider Ownership

9.07%

Institutional Own.

95.03%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PRT3645 (CDK4/6 inhibitor) Details
Head and neck cancer, Glioblastoma, Non-small cell lung carcinoma, Breast cancer

Phase 1

Data readout

PRT543 (PRMT5 inhibitor) Details
Solid tumor/s, Myelodysplastic syndrome, Myelofibrosis, Cancer

Phase 1

Data readout

PRT2527 (CDK9 inhibitor) Details
Acute myeloid leukemia, Solid tumor/s, Hematologic malignancies

Phase 1

Data readout

PRT3789 Details
Non-small cell lung carcinoma, Cancer

Phase 1

Data readout

PRT1419 (MCL1 inhibitor) Details
Hematologic malignancies, Relapsed/refractory acute myeloid leukemia, B-cell malignancies, Solid tumor/s

Phase 1

Update

PRT811 (PRMT5 inhibitor) Details
primary central nervous system lymphomas, Cancer, Glioblastoma

Failed

Discontinued